Sud Reprocessing- Regulation, Environment Impact Reduction & Cost Savings by Khanuja, Aman
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Public Health Theses School of Public Health 
January 2020 




Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl 
Recommended Citation 
Khanuja, Aman, "Sud Reprocessing- Regulation, Environment Impact Reduction & Cost Savings" (2020). 
Public Health Theses. 1958. 
https://elischolar.library.yale.edu/ysphtdl/1958 
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – 
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an 
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, 

















Aman Khanuja, MBBS 
Master of Public Health (Chronic Disease Epidemiology) 
Master of Business Administration (Management Science concentration) 
 
Yale University 











Jodi Sherman, MD 
Associate Professor of Anesthesiology, Yale School of Medicine 
Associate Professor of Epidemiology in Environmental Health Sciences, Yale School of Public Health 
 
Saed Alizamir, PhD 
Associate Professor of Operations Management 







Healthcare sector is estimated to contribute around 4.6% of the global Green House 
Gas (GHG) emissions. An estimated 11% of National Health Service GHG emissions are 
attributable to medical devices. Medical device industry, therefore, has a sizeable carbon 
footprint. Medical device reprocessing is a validated process used to render a medical device, 
which has been previously used or contaminated, ready for a subsequent use. It is estimated 
that 2-3% of all medical devices can be safely reprocessed. The Association of Medical Device 
Reprocessors (AMDR) estimates that the reprocessing activity by its member companies 
successfully reduced waste generation by 7093 tons, and generated cost savings of USD 170 
million for hospitals and surgical centers in United States, Canada, and Europe in the year 
2018. We estimate potential direct cost savings from reprocessing to be upwards of USD 2 
Billion per year for United States till 2025. Reprocessed single-use devices (SUDs) are safe 
and effective, and SUD reprocessing is a viable option for reducing the environmental impact 
of the healthcare industry and generate cost savings. There is a need to bring in regulatory 
reforms, promote buy-in from stakeholders including healthcare facilities and physicians, 
adapt performance-based business models like servitization, and generate environmental 
emissions databases for medical devices to guide empirical and data-driven policy making on 
reprocessing of SUDs. Further, original equipment manufacturers have indulged in anti-
competitive behavior to further their economic interests and need to be held accountable for 
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A 2016 [1] study estimated that the health care sector in United States contributed 9.8% 
of the country’s total Green House Gas (GHG) emissions. Air pollutants attributable to the 
health care sector were estimated to contribute 470,000 DALYs lost from pollution related 
disease. A 2019 report [2] estimated the healthcare sector to be responsible for about 4.6% of 
global emissions. A recent report [3] shows that 71% of the health sector's climate footprint is 
attributable to the supply chain that includes the production, packaging, transportation, and 
disposal of pharmaceuticals, medical devices, food, and hospital equipment.  Figure 1 depicts 
the size of the United States medical device industry from 2014 to 2025. While the share of 
medical device expenditure as a percentage of total medical expenditure is expected to hover 
around the five percent mark till 2025, medical devices expenditure is projected to have an 
upward trend in absolute terms. Research by the Sustainable Development Unit (a national unit 
based in Cambridge, England) suggests that in 2012, 11% of National Health Service (NHS) 
GHG emissions were attributable to medical devices [4]. The contribution of medical devices 
to the GHG emissions, therefore, cannot be ignored. Yet, there has been a dearth of research 
addressing the role of medical device industry in reducing the environmental impact from the 







Figure 1: Medical device expenditure (nominal dollars) in the United States between 2003 and 2016 [5] . 
  
Reprocessing of medical device is defined as a validated process (includes cleaning 
and disinfection or sterilization) used to render a medical device, which has been previously 
used or contaminated, ready for a subsequent use. According to the Food and Drug 
Administration, a single-use device (SUD), also referred to as a disposable device, is intended 
for use on one patient during a single procedure and is not intended to be reprocessed and used 
on another patient. In this paper, we look at a brief history of regulation of single use device 
(SUD) reprocessing, and the role of reprocessing of SUDs in reducing environmental impact 
and improving affordability of health care. We also look at how original equipment 
manufacturers (OEMs) have attempted to stymie the in-hospital and third-party SUD 
reprocessing. Finally, we suggest steps that could be taken to promote medical device 





Regulation of medical devices in the United States 
Originating in 1862 as a single chemist appointed to the United States Department of 
Agriculture, the Food and Drug Administration (FDA) is the oldest federal consumer 
protection agency in the United States. The 1938 Federal Food, Drug, and Cosmetic Act 
(FD&C Act) was the primary statute authorizing the FDA’s regulation and oversight of 
medical products. The Cooper Committee, established in 1970 by President Nixon, 
recommended passing legislation specifically targeted to medical devices as these devices 
presented regulatory issues that were significantly different than drugs. Following these 
recommendations, the 1976 Medical Device Amendments to the Federal Food, Drug, and 
Cosmetic Act was passed. This amendment resulted in increased regulatory oversight of 
medical devices through introducing several pre-market (Pre-market Approval, Pre-Market 
Notification/510(k)) and post-market (Adverse event reporting, device tracking) regulations 
for device manufacturers including mandatory registration of establishments and listing of 
devices with the FDA and Good Manufacturing Practices (GMPs). Medical devices were now 
categorized into Class I, Class II, or Class III based on the risks posed by their use to the 
patients and users, and the regulatory controls deemed necessary based on these risks.  
 
Regulatory requirements by device classes is as follows-  
1. Class I devices pose the lowest risk and require the least amount of regulatory oversight 
in the form of general controls. General controls are regulatory requirements authorized 
by the FD&C Act, under sections 501, 502, 510, 516, 518, 519, and 520, and apply to 




include elastic bandages, tourniquet cuffs, and disposable medical scissors/general-use 
surgical scissors.  
2. Class II require general controls and special controls. Special controls are device 
specific and include performance standards, post market surveillance, patient registries, 
and pre-market notifications (PMN). Example of Class II devices include ultrasound 
catheters, blood pressure cuffs, bronchoscope biopsy forceps, pulse oximeter sensors, 
compression sleeves, and most laparoscopic equipment. 
3. Class III devices pose the highest safety risk and are subject to the most stringent 
regulations in the form of general controls and Premarket Approval (PMA). Examples 
of Class III devices include implanted infusion pumps, cardiovascular intra-aortic 
balloon pump, transluminal coronary angioplasty catheters, and percutaneous tissue 
ablation electrodes.  
  
Premarket approval (PMA) is the FDA process of regulatory review to evaluate the 
safety and effectiveness of Class III medical devices. Given the high risk posed by the 
Class III devices, PMA is the most stringent type of device marketing application 
required by FDA. A PMA approval is based on a determination by FDA that the PMA 
contains sufficient valid scientific evidence to assure that the device is safe and effective 
for its intended use[6]. 
 
Pre-Market Notification (PMN) or 510(k) approval (under section 510(k) of the Food, 
Drug and Cosmetic Act) requires device manufacturers of Class I and Class II devices 




advance. This allows FDA to determine whether the device is equivalent to a device 
already placed into one of the three classification categories[7].  
 
A device is substantially equivalent to a predicate device if it has the same intended 
use, technological characteristics, and intended use as a legally marketed predicate 
device and the information submitted to FDA demonstrates that the device is as safe 
and effective as the predicate device[7]. 
 
The degree of regulation that a reusable medical device is subject to is also decided by 
the risk classification category (Table 1) it falls into. Critical devices are the highly regulated 
due to the high risk of infection posed by their use, while non-critical devices are subject to the 















Category Criteria Infection risk Examples 
Critical devices 
Encounter blood or 
normally sterile tissues thus 
pose the highest degree of 
risk of infection to the 
patients. 
High 
Surgical forceps, implants, 








endotracheal tubes, etc. 
Non-critical 
devices 
Encounter intact skin, thus 
posing the minimum degree 
of risk of infection. 
Low 
Stethoscopes, blood 
pressure cuffs, pulse 
oximeters, etc. 
 
Table 1: Categories of reusable medical devices based on risk of infection[8].  
 
It was not until 1997 that the FDA proposed regulating medical device reprocessors, 
whose activity did not significantly change the safety, performance or use of the medical 
devices, and the first policy document [9] pertaining to regulation of SUD reprocessing was 
released in the year 2000. The Agency explained that the increased regulation of the used 
device market was in order to ensure that the remarketed devices met suitable performance 
requirements for their intended uses and were as safe as the originally marketed finished 




to the lobbying by original equipment manufacturers (OEMs) whose economic interests were 
hurt from reprocessing of medical devices.  
 
Reprocessing of medical devices:  
Reprocessing of medical devices consists of the following three steps (in sequence)[10]- 
1. Point of use processing: The first step, includes prompt, initial cleaning to prevent 
drying of soil and contaminants in and on the device. For example, surgical instruments 
get wiped with gauze by scrub techs after each use before returning them to trays for 
reprocessing. This step is completed for all devices.  
2. Physical decontamination: This step involves a thorough cleaning of the device and 
is generally undertaken in a designated cleaning area. Cleaning could be manual, 
automated, or a combination of the two. The device label must include thorough 
instructions on temperatures, water quality, and other necessary conditions for effective 
manual cleaning; and equipment settings such as time and maximum device load size 
for automated cleaning. This step is also undertaken for all devices.   
3. Disinfection or Sterilization: This step is intended to kill microorganisms.  Depending 
on the device risk category and its intended use, it could need disinfection and/or 
sterilization before being reused. Devices unlikely to become contaminated with 
pathogens during use may not require disinfection/sterilization at all. Such devices 
would be suitable for reuse after the point of use processing and physical 
decontamination steps.  






Figure 2: Overview of the reprocessing process. From: Reprocessing Medical Devices in Health Care Settings: 
Validation Methods and Labeling Guidance for Industry and Food and Drug Administration Staff. March 17, 
2005  
  
The FDA guidelines suggest the manufacturers of medical devices to consider device 
designs that facilitate easy and effective cleaning, disinfection and sterilization. Complex 
device designs (like shaft-within-lumen configurations, elevator channels, fine channels, seals 
and mated articulating surfaces) present extra challenges in ensuring effective hygiene and 
manufacturers should consider alternative designs to facilitate effective reprocessing [10]. The 
manufacturers are also responsible for providing adequate labeling with instructions for 
reprocessing of devices and device accessories (including materials, equipment, and equipment 
specifications needed for adequate reprocessing of the devices) that, if followed by the 
reprocessors, would ensure patient safety and preserve optimum device functionality [10]. The 




health centers, medical offices, ambulatory surgery centers, and stand-alone reprocessing 
service facilities (third-party vendors).  
The FDA in its guiding document for reprocessing of reusable devices, recommends several 
documents and resources to be used in developing reprocessing instructions, along with 
relevant clinical practice guidelines and recommendations for infection control published by 
bodies such as the Center for Disease Control and Prevention (CDC)[11]  and the Society for 
Healthcare Epidemiology of America (SHEA)[12].   
 
Single-use medical devices. 
It is unclear when SUDs became a major part of the healthcare system but it is estimated 
that the first SUD was introduced in 1948 in the form of a plastic, non-breakable container for 
the storage of blood components [13, 14]. The medical devices were generally considered 
reusable before this period, and were mostly made from glass, metal, or rubber-based materials, 
thus making them heavier, costlier to ship, and more prone to breakage. SUDs, on the other 
hand, were cheaper to store and ship, were lightweight, improved occupational safety, and 
were less prone to breakage[13]. These properties shifted preference within the medical 
community towards SUDs. The demand for SUDs further increased in United States hospitals 
as a result of the instances of hospital acquired HIV AIDS [15] in the 1990s as the option of 
disposing them after single use would prevent transmission of disease by soiled medical device 
as vectors. 
The OEMs tried to capitalize on concerns of disease transmission risk through medical 
devices and have long pushed against reprocessing SUDs. These arguments of increased 




research. On the contrary, the Government Accountability Office (GAO) report in 2008 [16] 
claimed that there was no data to suggest reprocessed SUDs presented an elevated health risk. 
There has also been acceptance [17] among members of the medical community that OEMs 
have, on several occasions, indulged in the practice of arbitrarily labelling devices as SUDs 
purely based on economic incentives rather than scientific evidence on safe reusability. These 
members opine that these devices could be reused after careful reprocessing without 
detrimental effect on patient safety. The June 2000 GAO report [18] cited examples of this 
arbitrary labelling where in a 1998 U.S. District Court case, the judge found that the 
manufacturer’s only purposes in labeling a device for single-use were to comply with FDA’s 
requirements and to limit its own liability from reuse, not to prevent a hospital from using it 
more than once. The same report also mentions manufacturers writing letters containing 
detailed instructions for the sterilization of SUDs to hospitals. The letters typically cautioned 
against re-sterilizing the SUD and then proceeded to give detailed sterilization instructions. 
The health care facilities had also long realized the potential cost savings from 
reprocessing SUDs and had their in-house reprocessing facilities since as far back as the 1970s 
[19]. They continued to reprocess of SUDs in-house. The OEMs, however, did not like this 
practice of reprocessing of SUDs as each instance of reprocessing meant loss of a potential 
sale for them and lobbied for increased regulatory oversight for reprocessing of SUDs. Then, 
at the start of the century in 2000, the FDA began tightening the regulatory requirements for 
reprocessing of SUDs.  Consequently, the liability concerns for the hospitals far exceeded the 
fiscal advantages from in-house reprocessing and this paved way for an increase in the number 
of independent, third-party SUD reprocessors. These third-party SUD reprocessors would 




would implement processes to ensure a certain number of reprocessing and reuse cycles based 
on the device design and other technical parameters, apply for Pre-Market Approval (PMA) 
and 510(k) as the case may be, and assume all the liabilities pertaining to the safety and 
functionality of these reprocessed SUDs. The hospitals would now buy reprocessed devices 
from these third-party reprocessors without being subject to the increased liabilities from 
regulations, and the outsourcing also added to the cost-savings from streamlining of their 
operations. 
The push for stringent regulations for reprocessing of SUDs, however, backfired for 
the OEMs in the form of even higher acceptance for these devices from adherence to higher 
regulatory standards. Over the years, reprocessing of SUDs by third-party reprocessors has 
gained acceptance as a general practice that upholds patient safety and works well for the 
hospitals to contain their expenditure [20] on medical devices. The global revenue of 
independent SUD reprocessors was estimated to be USD 1.054 billion in 2016 with USD 848.5 
millions of these estimated sales being from the United States [21]. According to a 2019 report 
[22] by Mordor Intelligence, the SUD reprocessing market was valued at USD 1.8 billion in 
2018 with expected CAGR of about 15.24% between 2019 and 2024. 
 
Steps in reprocessing of SUDs 
  The reprocessing of SUDs could be done through in-house reprocessing operations at 
the central sterile services department (CSSD) of healthcare facilities or through third-party 
reprocessors. Figure 3 depicts the steps involved in the reprocessing of SUDs by the third-






Figure 3: The steps in third-party SUD reprocessing. The yellow boxes are the steps used by the reprocessors to 
benchmark their operative efficiencies- collection rates, acceptance rates, and buyback rates. The higher the 
collection, acceptance, and buyback rates, the better the operational efficiency.  
 
Definitions:  
1. Device collection rate- the number of reprocessable SUDs collected by reprocessors as 
a percent of the total number of reprocessable SUDs being used at the healthcare 
facility. Provision of collection bins of adequate shape/size at the healthcare facilities, 
and increasing awareness among the healthcare facility staff about the reprocessability 




2. Device acceptance rate- the number of devices accepted into the cleaning and testing 
stage at the reprocessing facility as a percentage of total devices collected by the 
reprocessor. Careful handling of the devices while in use at the healthcare facilities, 
during device collection, and during their transport to the reprocessing facility would 
improve the device acceptance rates. 
3. Device buyback rate- the number of reprocessed SUDs bought by the healthcare 
facilities from the third-party reprocessor as a percentage of total number of eligible 
devices collected for reprocessing. This means that device buyback rate can also be 
higher than 100% if a healthcare facility buys back more devices than it sends in for 
reprocessing but. Not every device that is collected is eligible for buyback. A given 
device can only be reprocessed a specified number of times (decided by the 
manufacturers- OEMs or reprocessors) and some devices would not be accepted into 
the cleaning stage due to damage caused in the prior stages. 
 
Regulatory history of the reprocessing of SUDs in the United States 
While hospitals have been engaging in reprocessing of medical devices (labelled SUD 
or reusable) since the late 1970s, the discussions about increasing the regulatory oversight on 
reprocessing of SUDs started in the 1990s. During this period, the OEMs pushed to curb the 
practice of reprocessing citing patient health risks such as cross-infections from reprocessed 
devices that were originally labelled as SUDs. Third-party reprocessors and hospitals with in-
house reprocessing operations, on the other hand, argued that reprocessed SUDs were safe, 




procurement and savings from reduced costs of waste disposal), and that the devices were often 
labelled as SUDs by the OEMs with their own economic interests in mind. 
The OEMs complained that while they were expected to meet all the regulations 
pertaining to manufacturing of medical devices (Premarket notification and approval (PMA) 
requirements, Medical Device Reporting (MDR) regulation for submission of adverse event 
reports, Quality Systems (QS) regulation, Labeling requirements, Medical Device Tracking, 
and Medical Device Corrections and Removals), the reprocessors of SUDs, even though the 
FDA recognized them as device manufacturers under the purview of definitions laid out in the 
FDCA, largely escaped the enforcement of these regulatory guidelines by the FDA. The only 
exception was the Medical Device Reporting and Quality System Regulation requirements 
[23]  that reprocessors were also subject to.  
In order to stymie the third-party reprocessing industry, the OEMs demanded the 
reprocessors be ordained by the FDA to follow the same stringent guidelines as the OEMs 
were.  A conference on the practice of reprocessing and reusing SUDs was organized jointly 
by the FDA and the Association for the Advancement of Medical instrumentation (AAMI) in 
Virginia on May 5-6, 1999 [24]. The participation of representatives of healthcare facilities, 
third-party reprocessors, OEMs, state governments, academia, medical ethicists, and standards 
organizations allowed the FDA to hear all perspectives to come up with a set of guidelines for 
the regulation of reprocessing of SUDs. 
There were divergent views on several important points during these interactions. 
While some members posited reprocessors of SUDs must be subject to the same regulatory 
approvals for each device as the OEMs, others opined that the onus should be on the OEMs to 




stipulate standards to assure and validate that reprocessing may be performed effectively, and 
to delineate a list of devices (the FDA, to date maintains this database online) that qualified for 
reprocessing. Based on these discussions and recommendations, the FDA released a proposed 
strategy on the reuse of SUDs on November 3, 1999 [25] and identified the following steps 
under consideration- 
 
1. Formulate a list of commonly reprocessed SUDs.  
2. Develop a list of factors to determine the degree of risk associated with reprocessing 
SUDs.  
3. Apply those factors to the list of commonly reprocessed SUDs to categorize them into 
– high, moderate, and low risk- based on prioritization by risk.  
4. Develop priorities for the enforcement of premarket submission requirements for third 
party and hospital reprocessors based on device risk category. 
 
The document had stated of the FDA’s view on regulation of reprocessing SUDs-  
  
Our primary goal is to ensure a reprocessing and reuse regulatory program based on 
good science that protects public health, while ensuring that our regulatory 
requirements are equitable to all parties. FDA does not believe that the changes to its 
final SUD regulatory strategy pose any significant public health risks [25]. 
 
Following this, the FDA released the Guidance for Industry and FDA Reviewers 




8, 2000 describing the proposal to categorize the risk of reprocessed SUDs. This process was 
titled the Review Prioritization Scheme (RPS). The FDA also shared these documents during 
the U.S. House of Representatives subcommittee hearing on February 10, 2000. A summary 
of discussion from this hearing is as follows-  
The proponents of patient safety concerns from reprocessing of SUDs submitted that if 
a device is labelled as single use by the OEM, it is likely not designed to be reprocessed and 
any attempt to disassemble, sterilize, and reassembling the device might damage the physical 
integrity and functional capabilities of the device. Any reprocessing would, therefore, raise an 
ethical and regulatory concern regarding the liability of a mishap from using reprocessed SUD. 
The OEMs opined that it was outright wrong for hospitals to indulge in using reprocessed 
SUDs, and that doing so puts their patients at grave risk.   
 
Josephine Torrente, the president of the Association of Disposable Device Manufacturers had 
said for reprocessed SUDs- 
 
“Until you prove otherwise, these devices are safe and effective for one use. After that, 
they’re garbage [17].”   
 
Robert O’Holla, the Chairman of the Association of Disposable Device Manufacturers had 
said that it was-  
“unacceptable to clean and reuse a delicate, complex medical device that was designed 





In response, physicians and representatives of healthcare facilities cited their own 
experience of using reprocessed devices for several years without adverse events. The 
physicians and third-party reprocessors complained that in several instances, the OEMs 
changed the label from reusable to SUD arbitrarily without making any structural changes to 
the device and cited the example of Johnson & Johnson (admittedly) changing the previously 
labelled reusable contact lenses as single use only for economic reasons[17]. Many devices 
labelled SUDs could be safely reused after being reprocessed, and discarding such devices 
after single use would lead to waste of resources. The third-party reprocessors also submitted 
that reprocessing of the SUDs was entirely safe for the patients and helped hospitals to keep 
the healthcare costs from spiraling up. 
  There was also the issue of ethics on whether patients should be informed about the use 
of reprocessed SUDs and should they have the final say on whether the reprocessed device 
should be used for their treatment or not. The physicians and healthcare facilities opined that 
since most patients do not think in statistical terms, and since reprocessing of SUDs differs for 
each device and with different intended uses of each device, taking an informed consent for 
every use case scenario was not feasible and would not ensure objective judgements by the 
patients. The aim should therefore be making the issue of consent moot through passing stricter 
regulatory control of reprocessing SUDs. 
The OEMs wanted the FDA to regulate the reprocessors of SUDs as manufacturers. 
They argued that onus of proving the safety of reprocessed SUDs relied entirely on the 
reprocessors and the hospitals that used these reprocessed SUDs. The AMDR reminded the 
OEMs that reprocessors of SUDs had to comply with several FDA requirements including the 




being reprocessed and ensure that it is sterile, safe, and performs its originally intended 
function. The OEMs, on the other hand, were required to test only a small sample of their total 
production. The reprocessors also submitted that they were not seeking an exemption from 
regulatory oversight. They realized that  reprocessing of SUDs could only survive in a “clear, 
rational regulatory scheme [17]” but the regulations need to be designed based on real and 
demonstrable concerns and not hypothetical concerns contrived by the OEMs. 
The June 2000 report by the United States General Accounting Office (GAO) 
concluded about SUDs that there was little available evidence of harm from reuse, but 
oversight (is) warranted [18]. Then, on August 14, 2000, the FDA released the Guidance for 
Industry and for FDA Staff Enforcement Priorities for Single-Use Devices Reprocessed by 
Third Parties and Hospitals Document.[26] .This document contained several modifications to 
the previous draft policy on the following points: 
 
1. In order to reduce the probability of delays in implementation of the final SUD policy, 
the FDA decided to abandon the risk prioritization scheme (RPS) to decide the timeline 
of FDA’s enforcement priorities for the pre-market approval requirements in favor of 
the device classification listed in the Code of Federal Regulations 6 (CFR). This 
includes three classes of devices- class I, class II, and class III. Sticking with an already 
existing and familiar classification would eliminate confusion or misunderstanding 
regarding a device’s risk category and the timing of premarket submissions.  
2. In the absence of any evidence of immediate threat posed to public health by 
reprocessing and reusing of SUDs, there would be a one year phase in for active 




listing, medical device reporting, tracking, corrections and removals, quality system, 
and labeling steps). 
3. The FDA decided to expand the list of Frequently Reprocessed SUDs, thus allowing 
for a greater number of SUDs to be recognized as reprocessable.  
  
The provisions within this guidance document were applicable to both- third-party and 
hospital SUD reprocessors and one of the most important decisions from the above-mentioned 
policy guidelines was the increased regulations for the hospitals that engaged in the 
reprocessing of SUDs. All establishments that engaged in reprocessing of SUDs were to 
register themselves with the FDA along with every individual type of device they reprocessed 
into the list of reprocessed SUDs maintained by the FDA. There were also other reporting 
requirements that applied to these establishments due to their classification as manufacturers 
under the FDCA. According to the August 14, 2000 document:  
 
“Hospitals who engage in manufacturing activities, such as reprocessing, are subject 
to manufacturer reporting requirements for the SUDs that they reprocess as well as 
user facility reporting requirements (21 CFR 803 Subpart E). In addition, they also 
must adhere to user facility reporting requirements for all other medical devices that 
they use (21 CFR 803 Subparts A and C).”  
 
Hospitals that did not engage in reprocessing of SUDs were classified as user facilities 





1. User facility: As per the guidelines, when a user facility receives information about a 
reportable adverse event, it must report the event to the FDA and/or the manufacturer 
within ten days of the receipt of this information. It must report the adverse event to 
both- the FDA and the manufacturer if the adverse event involves death while it only 
needed to report the adverse event to the manufacturer if a serious injury occurs but no 
death. In cases where the manufacturer is unknown, the FDA needs to be informed 
even if the adverse event does not involve death. 
2. Manufacturers: The manufacturers, after receiving an adverse event report from the 
user facility as described above, must collect additional information if necessary and 
submit the information to the FDA within thirty days from the date of receipt of the 
adverse event report. They must also file a Supplemental Report with the FDA within 
thirty days upon obtaining additional information on a previously reported adverse 
event. 
 
While user facilities were to report only deaths and serious injuries, the manufacturers 
were required to report malfunctions that do not result in death or serious injury (within thirty 
days) and remedial actions (within five days) in addition to deaths and serious injuries. These 
additional reporting requirements for the manufacturers are in the form of additional sections 










1. Serious injury (defined in 21 CFR Part 803.3(bb) (1)): An injury or illness that:  
i.  Is life-threatening.  
ii.  Results in permanent impairment of a body function or permanent damage to 
body   structure; or  
iii.  Necessitates medical or surgical intervention to preclude permanent impairment 
of a body function or permanent damage to a body structure. 
2. Malfunction (defined in 21 CFR 803.3(n)): The failure of a device to meet its 
performance specifications or otherwise perform as intended. Performance 
specifications include all claims made in the labeling for the device.  
 
The following are the considerations for identifying the manufacturer for medical devices [28]- 
 
Subject device is Manufacturer is 
Single use device Original Equipment Manufacturer (OEM) 
Device designed to be reused Original Equipment Manufacturer (OEM) 
Single use device, reprocessed for reuse Reprocessor 
Single use device, reprocessed by Hospital 
or Health care facility 
Hospital or Health care facility 
 







Medical Device User Fee and Modernization Act of 2002  
In 2002, the Medical Device User Fee and Modernization Act (MDUFMA) was passed 
which amended the Federal Food, Drug, and Cosmetic Act by adding the new section 
510(o)[29]. Under this act, several reprocessed SUDs from the critical[30] and semi-critical 
categories [31, 32] that were previously exempt from the 510(k) requirements were made non-
exempt in a phased manner. The definitions of critical and semi-critical reprocessed SUDs 
were akin to those already in use for the reusable device classification and were based on the 




1. Critical reprocessed single-use device: “The term ‘critical reprocessed single-use 
device’ means a reprocessed single-use device that is intended to contact normally 
sterile tissue or body spaces during use.”  
2. Semi-critical reprocessed single-use device: “The term `semi-critical reprocessed 
single-use device' means a reprocessed single-use device that is intended to contact 
intact mucous membranes and not penetrate normally sterile areas of the body.”   
   
Additionally, all reprocessors of SUDs were now required to submit validation data 
even if they already had a PMN/510(k) approval. A 510(k) approval is required of the 
following four entities[7]:  
1. Domestic manufacturers introducing a device into the United States market. Device 




components are not required to submit a 510(k) if these components are not sold to end 
users. 
2. Specification developers for finished devices introducing a device to the United States 
market. 
3. Repackers or relabelers who significantly change the labels (includes adding a new 
intended use, deleting or adding warnings, contraindications.) or otherwise affect 
significantly the condition of the device. Foreign manufacturers or exporters, or their 
United States representatives who introduce a device to the United States market. 
 
The validation data that was required of the reprocessors of SUDs consisted of information on- 
1. Process validation- This covers all the steps involved in the reprocessing of SUDs and 
aimed at allowing the hospitals and third-party reprocessors indulging in reprocessing 
of SUDs to present objective evidence that the process they employ can produce results 
that are consistently in accordance with specific, pre-determined specifications. 
2. Design validation- This covers the design of the reprocessed SUDs and the design of 
the processes that are employed to achieve consistent results from reprocessing. Design 
validation is aimed at allowing the hospitals and third-party reprocessors indulging in 
reprocessing of SUDs to present objective evidence that the device specifications for 
reprocessed SUDs marketed by them conform to user needs and the intended use of the 
device, and that the performance of the reprocessed SUD is substantially equivalent 
(SE) to the predicated device (a predicated device could be the original product 





As part of the validation process, the reprocessors of SUDs are required to submit data 
that includes cleaning agents and equipment used during the reprocessing, the installation, 
operational, and performance qualifications of the cleaning process, monitoring and control 
processes, sterilization processes employed for reprocessing of class III devices, final 
packaging materials used, package configuration and the shelf-life of the device with that 
packaging, and an evaluation of device function on a worst-case basis (i.e. after the maximum 
number of reprocessing cycles and re-uses that the device is rated for). 
   Each reprocessed SUD must also be provided with Instruction for Use (IFU) documents 
by the reprocessor and the label must prominently and conspicuously say- Reprocessed device 
for single use. Reprocessed by (name of the manufacturer that reprocessed the device). The 
IFUs are required for all medical devices (not just reprocessed SUDs) and contains information 
such as the intended use of the device, instructions for use, whether the device is 
reusable/suitable for reprocessing, and if the device is reusable- the instructions for 
reprocessing, the processes, reagents, and temperature conditions prescribed for effective 
reprocessing, and information on studies that justify the reprocessing instructions. Since the 
device manufacturers are responsible to formulate these IFUs themselves without any strict 
regulatory oversight, there is an inherent conflict of interest where OEMs would want to label 
the device for single use even if it can be safely reprocessed. They could also include a list of 
proprietary reagents or accessories as a recommendation/requirement for effective 
reprocessing when alternatives exist that are more readily available and cost-effective. Storage 
instructions noting how long a device can be safely stored in the prescribed packaging (shelf-
life) could also be understated based on economic interests. Thus, the regulation of IFUs is a 




Historically, reports have mentioned the insufficient adverse events reporting systems 
in place for reprocessed SUDs[33], and the limited data regarding outcomes from these devices 
also made it difficult to attribute adverse events to specific device reuse instances[34, 35]. Over 
the past several years, however, the regulatory mechanisms governing reprocessing of SUDs 
have evolved considerably. Reprocessing of SUDs is now covered by a wide range of 
regulations and in order to gain pre-market approvals for marketing these devices, the 
reprocessors need to provide sufficient data to ensure adequate safety and efficacy of these 
devices. The process and design validations that the reprocessors of SUDs are subject to are 
not required even for the OEMs and reprocessors of reusable devices. The reprocessors must 
also demonstrate that the device can be adequately cleaned and disinfected or sterilized, the 
processes involved in reprocessing ensure that the physical characteristics or quality of the 
device will not be adversely affected by the reprocessing, and that the device continues to 
function in compliance with the most recent FDA regulations. 
  
 Patient safety and reprocessing of medical devices. 
In September 2013, after conducting an extensive epidemiological investigation in 
conjunction with the King County and Washington State Health Departments, the staff at 
Virginia Mason Hospital and Medical Center in Seattle, Washington had traced a cluster of 39 
antibiotic-resistant infections to the use of reprocessed closed channel duodenoscopes used for 
endoscopic retrograde cholangio-pancreatography (ERCP). Carbapenem-resistant 
Enterobacteriacea infections were also identified in 32 patients that had undergone ERCP at 
the Advocate Lutheran General Hospital outside of Chicago around the same time[36]. The 




infested with bacteria even after the cleaning procedures prescribed by the manufacturer were 
followed accurately by the hospital reprocessing staff.  Even as the Medical Device Reporting 
(MDR) regulations (21 CFR Part 803) require the user facilities to report the adverse event to 
the FDA within ten days of receipt of such information, the device manufacturer was not 
notified of these findings within the stipulated time. The device manufacturer Olympus 
(manufactured 85 percent of the duodenoscopes used in the United States), through two 
independent laboratory reports was aware that the closed-channel model duodenoscope could 
harbor and spread bacteria even after it was cleaned as per the instructions provided by 
Olympus, and yet, did not notify the FDA about this, nor did it alert the hospitals, physicians, 
or patients in the U.S. to the risk of infection until February 2015[36]. 
Between 2012 and 2015, closed-channel duodenoscopes were linked to at least 25 
different incidents of antibiotic-resistant infections affecting at least 250 patients worldwide 
and even after being required to present sufficient data to show that duodenoscopes could be 
cleaned reliably between uses, none of the manufacturers of the closed channel duodenoscopes 
had such data. In the senate hearing that ensued after the Seattle Times wrote a story in January 
2015 on this incident it was noted- 
 
“Olympus, Fujifilm, and Pentax also failed to meet their obligations to provide FDA 
with the information the agency needs to keep patients safe. Olympus and Fujifilm 
never applied for FDA clearance for the new design of the closed channel 





The events expose several flaws in the enforcement of existing regulatory checks and 
balances for OEMs by the FDA, especially the post-marketing surveillance system designed 
for tracking and monitoring the safety of medical devices. There was a delay in reporting of 
critical information on device safety from the manufacturers and hospitals to the FDA. The 
adverse event reporting system of the FDA also caused a delay of almost seventeen months 
between when the agency was first made aware of the infections and the first safety 
communications back from FDA regarding the duodenoscopes in question. Sixty-eight patients 
across US were affected in this period across seven different hospitals. The senate hearing 
further noted: 
   
“FDA’s post-market surveillance system relies too heavily on self-reporting from 
manufacturers and hospitals with competing priorities that weigh against full and fast 
disclosure of patient safety concerns. This passive post-market surveillance system 
inhibits FDA’s ability to quickly identify information related patient health and device 
safety.” 
 
In response, the FDA took a series of corrective measures including instructing 
Olympus, Fujifilm, and Pentax to conduct post-market surveillance studies to better understand 
how the duodenoscopes were reprocessed in real-world settings. A series of communications 
followed between the FDA, the device manufacturers, the CDC, and the American Society for 
Microbiology (ASM)[37-40] on how to bring about the required improvements in the post 
market surveillance. Then, on August 29, 2019, the FDA issued a Safety Communication 
[41] to provide an update on the mandated post-market surveillance study results for 




transitioning to “duodenoscopes with innovative designs that facilitate or eliminate the need 
for reprocessing”.  
  This recommendation about eliminating the need for reprocessing effectively means 
that the FDA decided to take a stance against the reprocessing of medical devices whereas the 
optimal solution would have been to take measures that would ensure effective implementation 
of the post-market surveillance of reprocessed medical devices. The FDA, instead of 
reprimanding the OEMs and ensuring that guidelines are followed in the future, gave the OEMs 
a pat on the back for their inadequacy. 
  With the myriad of regulatory requirements that reprocessors of SUDs need to fulfil 
before marketing their devices, it is unfair to assume a worse risk profile from reprocessing a 
device based on its SUD label as opposed to a reusable label. While the OEMs pose no 
resistance to the reprocessing of reusable devices and state that the reprocessing of SUDs is an 
inherently unsafe practice, a device is only as safe as the effectiveness of the safety regulations 
that govern the device. If the designated processes for reprocessing of reusable devices are not 
followed properly, or if the design of reusable devices lends them unamenable to efficient and 
effective reprocessing, the reusable devices too would be unsafe. If effective reprocessing 
protocols are designed and proposed, and the SUDs are reprocessed following these designated 
protocols and processes, the adverse events would be minimal for these reprocessed SUDs. 
Further, a January 2008 report from the Government Accountability Office (GAO) aptly titled 
Reprocessed Single-Use Medical Devices FDA Oversight Has Increased, and Available 
Information Does Not Indicate That Use Presents an Elevated Health Risk [16]  mentions that 
the existing data does not indicate that reprocessed SUDs present an elevated health risk- an 




Role of reprocessing SUDs in environmental impact reduction  
Circular economy  
In the 1970s, the concept of circular economy emerged which formalized frameworks 
and guidelines for preserving the inherent value of goods (and the materials that constitute 
these goods). It did so by keeping the goods within the economic system through expanding 
the life cycle of the goods themselves or looping the constituent materials into the system 
through reuse or recycling. The most efficient way to capture the maximum value varies by 
case. Walter Stahel described the “Inertia Principle” in his 2010 book The Performance 
Economy as-  
 
“Do not repair what is not broken, do not remanufacture something that can be 
repaired, do not recycle a product that can be remanufactured.” 
  
The design of products, materials choice, and infrastructure to provide channels or 
loops for circulating the goods- are all important considerations for effective implementation 
of circular economy. Health care sector, however, poses some additional challenges. As patient 
health is an obstinate priority, the design, material choice, and life-cycle decisions that are 
geared towards promoting circular economy cannot, at any point, compromise with the 
functional reliability and safety of medical devices. However, all approved reprocessed SUDs 
being substantially equivalent to the predicate devices and not posing any additional risks to 
the patient safety, are a viable route towards realizing a circular economy for medical devices. 
With the size of medical devices industry expected to grow at more than 5.4% per year till 
2025[42], and a strong consensus on the need to reduce the carbon footprint for a better future, 




waste generation and conserve resources through their recirculation back into the economy. 
Figure 4 depicts the concept of circular economy as proposed by the Ellen MacArthur 
Foundation and Figure 5 depicts design strategies for medical products with product criticality 
and product value as a framework to promote circular economy by Kane et al [43].  
  
 







Figure 5: Design strategies for medical products with product criticality and product value as a framework to 
promote circular economy [43] 
 
Medical waste  
The Environmental Protection Agency defines medical waste as a subset of wastes 
generated at health care facilities, such as hospitals, physicians' offices, dental practices, 
blood banks, and veterinary hospitals/clinics, as well as medical research facilities and 
laboratories. The agency divides medical waste into four major categories-  
 
1. General Waste- This category forms the bulk of medical waste generated at healthcare 
facilities. Includes mostly solid wastes typical of any household and office settings.  
2. Infectious Waste- Includes blood, human tissue, and anything contaminated with blood, 
human tissue, or bodily fluids. This is also labelled as regulated medical waste (RMW) 




3. Hazardous Waste- Handling and disposing this form of waste is dangerous, but not 
because of its infectivity. Includes sharps, discarded surgical equipment, and some 
chemical waste.  
4. Radioactive Waste- Any waste attributable to radioactive treatments like cancer 
therapies and medical equipment that uses nuclear elements.  
 
Definition: 
 Regulated Medical Waste (RMW)[44]- Regulated medical waste (RMW), also known 
as ‘biohazardous’ waste or 'infectious medical’ waste, is the portion of the waste stream 
that may be contaminated by blood, body fluids or other potentially infectious 
materials, thus posing a significant risk of transmitting infection. 
  
Although regulations related to medical waste management fall under the purview of 
several federal agencies (including Occupational Health & Safety Administration (OHSA), the 
CDC, the FDA, Environmental Protection Agency (EPA)), medical waste is primarily 
regulated by state environmental and health departments. The Congress enacted the Medical 
Waste Tracking Act (MWTA) of 1988 as a two-year federal program through which the EPA 
promulgated regulations on management of medical waste. 
 
The MWTA had amended the Solid Waste Disposal Act of 1965 and achieved the following 
[45]-  
1. Defined medical waste and established which medical wastes would be subject to 




2. Established a cradle-to-grave tracking system utilizing a generator-initiated tracking 
form.  
3. Required management standards for segregation, packaging, labeling and marking, 
and storage of the medical waste.  
4. Established record keeping requirements and penalties that could be imposed for 
mismanagement.   
 
These regulations went into effect on June 24, 1989 in only four states - New York, 
New Jersey, Connecticut, and Rhode Island and Puerto Rico, and expired on June 21, 1991. 
States were granted authority to regulate medical wastes after the MWTA expired in 1991. In 
several states (for example, Oklahoma, Colorado) the state Department of Health (DOH) plays 
the central role in medical waste management and disposal, while in states like Montana and 
Louisiana, the state EPA and DOH share these responsibilities. Today, nearly all 50 states have 
enacted their own medical waste regulations and the state medical waste standards vary widely 
with some state medical waste regulations based on the MWTA, while others having no 
resemblance to the MWTA at all. This fragmented approach to regulation of medical waste 
management makes it almost impossible for facilities to coordinate on formulating a uniform 
and central policy. 
  Reduction in the hospital waste generation due to fewer SUDs discarded and instead 
being reprocessed and reused is an important benefit of reprocessing SUDs. A 2005 study[46] 
estimated that in the year 2004, reprocessing helped healthcare organizations reduce the waste 
generation by 449 tons. The same study also mentions that healthcare facilities with 250 beds 




Healthier Hospitals, a Practice Greenhealth program found that the Hospital Corporation of 
America (HCA) had 296 tons and 364 tons of hospital waste diverted in 2010 and 2011, 
respectively from reprocessing of SUDs. The AMDR estimates that the reprocessing activity 
by its member companies successfully reduced waste generation by 7093 tons in 2018.  
 
 
Figure 6: The growth of medical device of reprocessing over the years for healthcare facilities participating in the 
practice Greenhealth survey. Source- 2016 sustainability benchmark report by Practice Greenhealth [48] 
 
 
There is no accurate and detailed tracking of the contribution of medical devices to the 
total medical waste generated at healthcare facilities which makes it difficult to formulate an 
empirical and data-driven policy to reduce the environmental impact from medical devices. 
This dearth of data also contributes to lack of awareness among medical personnel and the 
patients on what impact their choice of medical devices (reprocessed vs unused) would have 
on the environment. If more information is available, this would help increase buy-in for more 




Role of reprocessing SUDs in cost savings for healthcare facilities  
A Healthier Hospitals case study[47] found that the Hospital Corporation of America 
(HCA) had realized USD 17.6 million and USD 21.7 million in cost savings in 2010 and 2011, 
respectively from reprocessing of SUDs. The AMDR claims that the reprocessing activity by 
its member companies saved USD 170 million for hospitals and surgical centers in United 
States, Canada, and Europe in the year 2018[49]. While the bulk of these savings can be 
attributed to direct cost savings on device procurement, there are also savings from reduced 
waste generation. 
  The OEMs intend for the devices designated as SUDs by them not to be reprocessed 
but disposed of as biohazardous waste after single use. This practice has significant 
environmental and direct cost implications. According to the 2016 sustainability benchmark 
report by Practice Greenhealth[48], the median cost for disposing of solid waste in the United 
States was USD 103 per ton, while it cost an average USD 1,142 per ton for disposal of non-
hazardous medical waste and more than USD 4,000 per ton on an average to dispose hazardous 
waste. Some estimates [50] suggest disposal of regulated medical waste (RMW) can cost between 
five to ten times more than disposal of solid waste. A reduction in the amount of RMW could, 
therefore, translate to significant cost savings for healthcare facilities. According to the CDC, 
the RMW generated for any hospital should not be more than three to five percent of the total 
waste generated at the facility[50]. 
The Greenhealth Sustainability Benchmark Report of 2017 [51] states that of the 355 
hospitals that responded to survey questions on either the Partner for Change or the Partner 
Recognition award application parts of the report, only sixty percent had implemented a SUD 




participants is an indication of the potential and unrealized savings to the healthcare facilities 
from reprocessing of SUDs. Other findings from this report were as follows-  
 
  Collect reprocessed devices Purchase reprocessed devices 
Of the 214 facilities that have a reprocessing program, the percent of facilities that collect devices for 
reprocessing or buy-back reprocessed devices- by department:  
OR  96% 86% 
EP/cath  62% 58% 
Patient care  80% 68% 
Other  22% 17% 
Of the 214 facilities that have a reprocessing program, the percent of facilities that collect devices for 
reprocessing or buy-back reprocessed devices- by device category: 
Non-invasive  90% 83% 
Invasive  88% 78% 
   
Median cost savings  Per facility Per operating room 
Cost savings from purchasing 





Cost savings from avoided waste 






   
Aggregate cost-savings from 






Another method to analyze the potential cost savings to the healthcare facilities from 
the reprocessing of SUDs is to look at the percentage of total medical devices used annually 
that are reprocessed SUDs. It is estimated that between 2-3% of all medical devices can be 
safely reprocessed [21]. Figure 7 depicts a sample calculation of cost-savings for hospitals 
from using reprocessed devices vs new devices. Figure 8 depicts the size of the United States 
medical device market from 2014 to 2018 as a percentage of total National Health Expenditure 
and the year over year growth of this market. Figure 9 depicts the projected potential cost 
savings from reprocessing of medical devices in the United States from 2019 to 2025 with the 
assumption that 3% of all medical devices (by dollar amount) are reprocessed. This assumption 
that 3% medical devices could be reprocessed has an important weakness regarding 
extrapolation of results- savings from reprocessing are not similar across all devices. They are 
greater with costlier devices and smaller with cheaper devices. It is, however a close enough 














Price from OEM  $100 
Price from reprocessors  $50 
 
Total number of devices demanded by 
the healthcare facility  
100 
 
Collection rate for reprocessing  50% 60% 70% 80% 
# Individual devices collected   50 60 70 80 
Buyback rate from reprocessor  60% 70% 80% 90% 
# Individual devices bought back  30 42 56 72 
Savings from reprocessing  $1,500 $2,100 $2,800 $3,600 
Figure 7: A sample calculation of cost-savings for hospitals from using reprocessed devices vs new devices  
 
 







Figure 9: The projected potential cost savings from reprocessing of medical devices in the United States from 
2019 to 2025  
 
A metric whose value is not necessarily captured in these analyses is the potential 
increase in accessibility and affordability of healthcare services. There would be a positive 
expected impact on healthcare access of the population served by a healthcare facility as a 
result of cost-savings from the reprocessing of SUDs being passed on to this population. It is, 
however, difficult to analyze this effect in greater detail as in the United States, the price paid 
by the consumer (patients), the government health plans, or the insurers for a medical device 
is not reported in isolation but as the price for the entire bundle that includes the price of the 






How OEMs have tried to resist reprocessing of SUDs in the past two decades. 
As the reprocessing of SUDs has gained acceptance and size of the reprocessing SUDs 
industry increased over the years, OEMs have made several attempts to inhibit the reprocessing 
of SUDs. Here we discuss examples of such tactics employed by the OEMs in greater detail. 
 
1. Arbitrary change in the labelling of reusable devices to SUDs.  
2. Lobbying for more stringent regulatory control of the reprocessing of SUDs.  
3. Buying out the independent reprocessors of SUDs and reduce the number of 510(k) 
submissions from these firms post acquisition.  
4. Threatening to withdraw technical support for the SUDs if healthcare facilities use 
reprocessed SUDs.  
5. Offering disingenuous product mixes to healthcare facilities.  
6. Using proprietary software as gatekeepers on SUDs to lock out the reprocessors.  
7. Designing obsolescence into SUDs.  
8. Offering discounts to healthcare facilities in lieu of contractually restricting the use of 
reprocessing of SUDs.  
9. Physically interfering with hospital owned assets to induce inefficiencies in the 
reprocessing of SUDs. 
  
We have already covered the arbitrary nature of SUD labels and the lobbying efforts 






Buying out the independent reprocessors 
  Most third-party reprocessors were small in size to start with and dealt in a single or 
few device families (for example, cardiac catheters were one of the most reprocessed due to 
the higher volume of related procedures in the United States and the high price of the SUDs 
involved meant higher savings for hospitals). As time progressed, along with an increase in the 
volume of third-party reprocessing, the industry also saw consolidation among the third-party 
reprocessors. For example, in 2005, the two leading independent reprocessors at the time- 
Vanguard Medical Concepts and Alliance Medical Corporation merged to form Ascent 
Healthcare Solutions. The third-party reprocessors kept up the pace of 510(k) filings and forced 
the OEMs to compete with them. 
As a competitive response, OEMs decided to acquire the biggest reprocessors. If OEMs 
controlled the reprocessors, they would essentially gain control of their competition. In 
November 2009, Stryker announced that they would acquire Ascent Healthcare Solutions 
(whose annual sales in 2008 exceeded USD 100 million) in an all cash, USD 525 million deal 
[52].  In 2011, Johnson & Johnson, through its Ethicon Endo-Surgery division, acquired the 
Minnesota-based third-party reprocessor SterilMed Inc (the second largest SUD reprocessor at 
the time) for an undisclosed amount [53]. SterilMed Inc was founded in 1997 and at the time 
of this acquisition had already received 40 FDA 510(k) clearances[54]. Although it was touted 
that these acquisitions would be beneficial for the medical devices market as the big firms 
would bring in more resources and R&D capabilities to the smaller SUD reprocessing firms, 
the opposite happened. The 510(k) clearances essentially dried up since these big acquisitions. 
For example, Stryker averaged a little less than two additional 510(k) clearances per year since 




SterilMed Inc has received less than one 510(k) clearances per year since its acquisition 
compared to four before [55](Figure 10). By contrast, Innovative Healthcare (considered to be 
the reincarnation of Ascent Healthcare Solutions), an independent reprocessor has received 18 
cardiovascular device clearances between 2016 and 2018 alone (Figure 11). 
 
  
Figure 10: Effect on annual 510(k) approvals of acquisition by OEMs. The year of acquisition and the (one) year 
after are excluded from calculations to adjust for transitory effects of acquisitions. Ascent Healthcare Solutions 








Figure 11: Independent vs OEM owned reprocessors (annual 510(k) approvals) Data source:  
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm 
  
Threatening to withdraw technical support. 
Purchasing new devices from the OEMs that are incompatible with existing systems 
could prove to be even costlier in the long run for hospitals. A new, upgraded device might not 
be compatible with all the existing accessories from the previous version of the device. 
Abandoning a current version of the device in favor of an updated version is only justified if 
the upgrade would result in performance improvement proportionate to the increased costs. 
Without performance improvements significant enough to justify the cost escalation from the 
new investments, the hospitals should reconsider their decision to upgrade. Savings realized 
without compromising on the device performance and patient safety would contribute to 
improving the affordability of healthcare for the population served by the healthcare facility. 
Hence, it is very important that healthcare facilities continue to have access to reprocessed 




The AMDR mentions receiving several reports the OEMs threatening to withdraw 
necessary technical support for the SUDs if the facilities continued using reprocessed SUDs. 
The OEMs cite difficulties for technicians to provide support for reprocessed versions of the 
SUDs as the purported reason for this action. But given that each reprocessed SUD as approved 
to be substantially equivalent with the predicate devices the technicians face no difficulty 
providing technical support for, this practice of withdrawing technical support by OEMs 
constitutes anti-competitive behavior on their part. This practice takes an even more egregious 
form with instances of technicians leaving the electrophysiology (EP) labs during a procedure 
when a reprocessed device that is not reprocessed by the OEM is being used by the physicians. 
Hospitals could play an important role in curbing such practices by negotiating a zero-tolerance 
policy towards such anti-competitive behavior in their contracts with OEMs. 
 
Offering disingenuous product mixes to the unsuspecting hospitals.  
The OEMs sometimes rely on offering disingenuous product mixes to unsuspecting 
healthcare facilities to curb the use of reprocessed SUDs. This tactic is especially relevant for 
OEMs with SUD reprocessing operation from acquisition of third-party SUD reprocessors. 
Such OEMs can offer a product mix consisting of an agreed upon ratio of non-reprocessed and 
reprocessed SUDs. Such a product mix is attractive to the healthcare facilities as they get access 
to cost savings from the inclusion of reprocessed SUDs into their supplies while still 
maintaining their relationship with the OEMs who control a wide portfolio of medical devices 
required by the healthcare facilities. The OEMs, however, have been reported to not fulfilling 
the terms of such contracts and favor non-reprocessed SUDs over reprocessed SUDs. The 




the OEMs and seeking frequent reports on the supplied mix of new vs reprocessed devices. 
Healthcare facilities should also develop relationships with more than one OEMs when 
possible to achieve a higher bargaining power over the OEMs. 
 
Using proprietary software as gatekeepers on SUDs to lock out the reprocessors.  
As technological advances are being made, medical devices increasingly contain one 
or more programmable components in their design. The OEMs use proprietary software as the 
gatekeepers for these devices and according to the AMDR, the OEMs have been reported to 
update [56] the software with purported intention of addressing cybersecurity vulnerabilities 
to the device but this also results in the loss of compatibility of reprocessed parts with the 
predicate (OEM supplied) device. With many electrosurgical instruments and cardiology 
catheters costing thousands of dollars each, such anti-competitive practices hurt the interests 
of both- the independent SUD reprocessors and the healthcare facilities. The doctrine of patent 
exhaustion and first-sale doctrine suggest that OEMs do not have any authority to dictate the 
healthcare facilities on what accessories to use with the devices once they have been purchased 
by the healthcare facilities. Companies often try to unfairly impose restrictions on the use of 
their products even after they have been sold. In its landmark ruling [57] in the case of 
Impression Products, Inc. Vs Lexmark International, Inc. in 2017, the Supreme Court of United 
States noted- 
 
“We conclude that a patentee’s decision to sell a product exhausts all of its patent 
rights in that item, regardless of any restrictions the patentee purports to impose or the 





The ruling is an endorsement of the idea that reprocessing of SUDs must not be subject 
to the anti-competitive practices by the OEMs.   
 
Definitions:  
1. First-sale doctrine[58]- The first sale doctrine, codified at 17 U.S.C. § 109, provides 
that an individual who knowingly purchases a copy of a copyrighted work from the 
copyright holder receives the right to sell, display or otherwise dispose of that 
particular copy, notwithstanding the interests of the copyright owner.  
2. Doctrine of patent exhaustion[59]- The doctrine of patent exhaustion holds that once 
a patent owner has sold a patented product for the first time, they no longer have 
control over it: the buyer can use, sell, license, or destroy it as they wish.  
 
The recent right to repair movement on how big technology firms try to prevent 
consumers from accessing repair services for the devices they own is also analogous to the 
issue at hand. The device manufacturers must learn to accept the rights of consumers/users in 
being able to control the devices they have purchased. The OEMs do not have any rights to 
hurt consumer interest and dictate the terms of use beyond what is reasonable. 
  
Designing obsolescence into SUDs to reduce their lifespan. 
The AMDR reports several examples of this tactic[60]-  
1. Placing chips in single-use devices so that they cannot be reused after reprocessing. 
These chips have become more and more complex with time.  
2. Covering critical pieces of the device in glue or materials that cannot be removed to 




3. Degrading the material used for the device so that it breaks more easily.  
4. Designing devices with unnecessary holes or creases that make it difficult or impossible 
to clean the device.  
 
Healthcare facilities must be vigilant about the possibility of such “kill switches” in the 
devices they procure and must also be wary of upgrade proposals by the OEMs without 
verifying a genuine need to upgrade. The FDA should also take cognizance of such anti-
competitive practices by the OEMs and enact regulations to curb the development of medical 
devices features whose sole purpose is to force obsolescence.  
 
Offering discounts in lieu of contractually restricting the use of reprocessing of SUDs. 
The OEMs have been reported [60] to offer outright discounts and compensations to 
healthcare facilities in lieu of imposing contractual restrictions on the inclusion of reprocessing 
SUDs in their supplies. Even as healthcare facilities might see this as a cost saving in the short 
run, the costs accumulate over several years due to loss of savings from reprocessed SUDs 
over new devices from OEMs. Contractual limitations on reprocessing reduces the competition 
for OEMs allowing them to increase their mark-ups and thwarts innovation by independent 
reprocessing firms. 
 
Physically interfering to induce inefficiencies in the reprocessing of SUDs.  
Reprocessors develop a series of steps that allows them to improve device collection 
and efficient transport of the collected devices to the reprocessing facilities. The hospitals 




mentions the following instances of OEMs physically interfering with such hospital owned 
assets in a bid to induce inefficiencies in the reprocessing cycle[61]- 
 
1. Removing cables from EP labs, replacing them with cables that only communicate with 
the new models of diagnostic catheters, so the hospital is forced to curtail procuring 
reprocessed devices.   
2. Dispose of used devices that are the property of the hospital and could have been 
collected instead by the reprocessors.  
3. Reorganizing hospital shelves to favor new over reprocessed devices.  
4. Demanding surgeons to bend or destroy SUDs after they have been used so that these 
devices must be discarded at reprocessing facilities instead of being bought back by the 
hospitals. 
 
It takes considerable time and efforts to fine tune the supply chain between the 
healthcare facilities and reprocessing facilities. The steps put in place by the reprocessors for 
seamless collection, cleaning, disinfection/sterilization, repackaging and transport back to the 
healthcare facility are not devised and perfected overnight. Even with incremental innovation 
by the OEMs on SUDs, the SUD reprocessors have a relatively short window to design and 
implement the processes that would result in optimal returns from reprocessing of each device 
in their portfolio. Applying for pre-market approvals or 510(k) and getting other regulatory 
clearances also force the SUD reprocessors to run a tight and efficient process where they must 




reprocessors to lose out on returns as the devices would become obsolete in a few months to 
years from being superseded by newer versions.  
Healthcare facilities must outline and address all such tactics while negotiating 
contracts and should not deter from pursuing legal action against the OEMs and their 
representatives pertaining to breach of contract. The FDA should also intervene on behalf of 
the reprocessors and healthcare facilities and ensure that patient welfare is not compromised 
due to unfair pursuit of financial motives by the OEMs.  
  
The role of servitization in medical device industry 
There has been a general trend towards servitization through performance-based 
contracts in the manufacturing industry where product ownership is not the priority and 
superior after-sales maintenance and support services are sought. Vandermerwe and Juan 
Rada[62] defined servitization as offering fuller market packages or bundles of customer-
focused combinations of goods, services, support, self-service, and knowledge.  
Some examples of servitization outside the healthcare sector include the power by the 
hour model [63] where Rolls-Royce sells performance hours to its customers (airlines) and not 
the aero-engine itself, and when Philips [64] offered light as a service to the Amsterdam airport 
Schiphol instead of the physical LED bulb units. In the healthcare sector, GE healthcare selling 
product-service packages[65] that include product maintenance (remote monitoring and 
maintenance of its own products and those of other manufacturers) together with the physical 
products themselves is an example of servitization. 
  Servitization is a viable tool to promote circular economy where the OEMs are 




itself.  This also offers a new paradigm for the interaction between the medical device 
manufacturers and the physicians and technicians that use the devices by shifting the focus 
from selling to various forms of leasing and pay-for-performance[66]. Under the servitization 
model, the healthcare facilities, instead of procuring the devices from OEMs, would sign 
contracts for a certain number of uses of the devices. This shift of focus from the ownership of 
medical devices towards the service and performance of the devices would also align 
incentives between the device manufacturers and users. For example, it would be in the interest 
of the OEMs to produce, supply, and discard as few device units as possible (rather than as 
much in the current business model) if they are paid only for certain number of uses of the 
device rather than the actual number of devices used. 
The OEMs can utilize such performance-based contracts as a differentiator [65] to gain 
market share over their competitors.  For the consumers (healthcare facilities, physicians), 
servitization essentially replaces high investment costs from product ownership of new devices 
with variable operating costs. The OEMs are then responsible for the optimum operation of 
these devices throughout their service life till the contracted number of uses are exhausted. 
This reduces the financial risk for the healthcare facilities and physicians and improves their 
asset management. Environmental impact reduction would also be sizeable from reduced 
medical waste (from diversion to reuse vs disposal) given the high carbon footprint of the 
medical device industry.  
Careful analysis of the product life cycle is essential to develop optimal servitization 
contracts tailored for the medical device industry and the highly regulated nature of this 
industry also adds to the complexity of this model. While the possibility and scope of a 




previous studies [67, 68], practical investigations have been lacking[69]. Additional work in 
this area is, therefore, required in order to realize the full potential cost savings and reduction 
in the environmental impact from servitization within the medical device industry.  
 
Steps that should be taken to promote medical device reprocessing. 
The FDA needs to be more balanced in its regulation of OEMs and third-party SUD 
reprocessors. The stringent regulations concerning the reprocessing of SUDs is reassuring 
towards ascertaining the safety and functional equivalence of reprocessed SUDs to the 
predicate devices, but the OEMs still enjoy significant and disproportionate leeway. Currently, 
SUD reprocessors are required to apply for premarket validation for each of the class II and 
class III SUDs on their portfolio while OEMs are exempt from such requirements. This needs 
to change. The OEMs must not be given a free hand to be able to manipulate the Instruction 
for Use process unduly in their favor for economic gains by actions such as pushing for SUD 
status when reprocessing is safe, promoting proprietary cleaning reagents and accessories 
when functionally equivalent and more cost-effective alternatives are available, and 
understating the shelf-life of a device in storage to increase their rate of being discarded on the 
pretext of safety concerns. OEMs must be made accountable for their anti-competitive 
practices. 
Environmental impact of the medical device industry must be considered as a cost by 
healthcare facilities while negotiating contracts with OEMs. This is especially important as the 
reprocessed SUDs are already proven to be safe and favoring reprocessed devices over unused 
devices has additional benefits of cost reduction and environmental impact reduction. 




data on each of their listed devices by the FDA. While FDA should consider regulating medical 
device manufacturers on the basis of this additional data on the carbon footprint from medical 
devices, even if it chooses to not regulate citing insufficient resources, this information could 
be declared as mandatory to be collected by Group Purchasing Organizations, and a database 
be created to give healthcare consumers more information on the environmental impact of their 
choice of medical devices. While increasing consumer awareness is important, it is also 
important to ensure that the device manufacturers and other players in the medical device 
supply chain are not allowed to shrug off the responsibility of taking decisions that promote 
environmentally friendly practices completely on to consumers like it was done by the plastics 
industry. The industry must be held accountable for their actions. 
The medical device industry should be progressing towards servitization. The 
healthcare facilities must take the lead in creating a demand for performance-based contracts 
with the OEMs, and OEMs must see this as an opportunity to differentiate. This would also be 
an opportunity for OEMs to align incentives with the providers by promoting better 
performance, cost savings, and environmental impact reduction. Healthcare facilities must be 
more vigilant while signing device procurement contracts with OEMs and must consider the 
value of a stable supply chain with redundancy baked in and by factoring into their cost 
assessments, the potential for long-term cost savings from maintaining compatibility of 
medical devices and accessories. Steps must be taken to promote buy-in from all stakeholders 
including physicians and technicians for reprocessed SUDs.  
The FDA has an important role in this regard, but the hospital management also needs 






As the healthcare costs continue to escalate and there are increased efforts globally to 
reduce the carbon foot print from industries, reprocessing of SUDs is a safe and 
environmentally responsible choice for medical device industry. The low buy-in from facilities 
and physicians and the meagre 2-3% medical devices in use being eligible for reprocessing are 
important concerns.  Other concerns include the misaligned incentives between the OEMs and 
healthcare facilities and absent environmental cost considerations in calculating the overall 
cost of using medical devices. Novel business models like servitization need to be promoted 
and there must be a push towards a proactive policy to reduce medical waste generation in all 
states. The regulatory bodies like the FDA need to take a stronger stand against the anti-
competitive behavior of the OEMs and must instead incentivize inclusion of environmentally 
responsible choices into the medical device supply chain. There is a dearth of data from life 
cycle analysis of the medical device and such work would greatly inform the decision making 
towards a more environmentally friendly healthcare industry in the future. 
 
Future work 
To date, there hasn’t been much work done on assessing the environmental impact of 
the medical device reprocessing industry. More specifically, there are no academic peer 
reviewed studies, outside of early market size estimates. Historical attempts at performing such 
analyses of environmental impact using software tools and databases with predefined processes 
[70, 71] have identified issues including dearth of data and lack of appropriate, pre-defined 
modelling processes, especially for complex medical devices. With the rapid growth 




as well as the anticipated future regulations on environmental impact reduction, there is a need 
to develop methods of estimating environmental emissions associated with medical device 
reprocessing. 
  We propose a Life Cycle Analysis (LCA) to estimate greenhouse gas emissions 
reduction opportunity from the medical device reprocessing industry. LCA is an internationally 
standardized (ISO 14040) scientific method of quantifying environmental emissions of a 
product or process from ‘cradle to grave’, and includes the steps of natural resource extraction, 
manufacturing, packaging, transportation, use, and eventual materials disposal.  Two general 
types of LCA exist: top-down economic input-output approach (EIOLCA), and bottom-up 
process-based approach.  The former is considered appropriate for very large studies and relies 
on price as a surrogate marker for embodied emissions. The latter LCA is based on actual 
material types and quantities, and is, therefore, deemed more accurate for individual product 
decisions. Relevant transportation data is also essential for assessing this market, whether 
performing a bottom up LCA or an EIOLCA.  
It is understood that individual materials and components may move substantially 
around the global marketplace. Due to such complexities, it is a well-accepted assumption 
within LCA to use the final point of device assembly in making inferences. This would include 
the data on final point of manufacturing, regional centers for distribution and reprocessing, and 
the associated medical device/price volume. To facilitate the performance of environmental 
impact assessments, a single database containing the constituting material and weights for each 
medical device, data on packaging material, etc. would be needed. It would be useful for both 




notably GHG expressed as carbon dioxide equivalents, CO2-e), to their customers and 
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